• P Van Cauwenberge and E F Juniper.
• Department of Otorhinolaryngology, University Hospital, Ghent, Belgium. paul.vancauwenberge@rug.ac.be
• Clin. Exp. Allergy. 2000 Jun 1; 30 (6): 891-9.

BackgroundAs there have been no previously published studies, this multinational, double-blind, randomized, placebo-controlled, parallel group study compared the efficacy, safety and impact on quality of life (QoL) in seasonal allergic rhinitis patients (SAR) of fexofenadine and loratadine (with placebo), when administered once daily.MethodsSix hundred and eighty-eight SAR patients were randomized to receive fexofenadine HCl 120 mg, loratadine 10 mg or placebo, once daily for 2 weeks. The key parameters were the change from baseline in: mean 24-h reflective total symptom scores (TSS); sum of four individual symptom scores, excluding nasal congestion; instantaneous TSS; individual symptom scores including nasal congestion; and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Adverse events were recorded.ResultsMean 24-h reflective and instantaneous TSS were significantly reduced by both fexofenadine HCl (both P ConclusionFexofenadine HCl and loratadine administered once daily are effective and well tolerated in SAR. In this study, fexofenadine HCl was significantly more effective than loratadine in relieving eye symptoms and nasal congestion. Furthermore, fexofenadine was significantly better than loratadine in improving QoL.

29 keywords...

hide…